

1 **Protective antibodies and T cell responses to Omicron variant three months after**
2 **the booster dose of BNT162b2 vaccine**

3

4 **Authors:** Paul Naaber^{1,2} paul.naaber@synlab.ee

5 Liina Tserel³ liina.tserel@ut.ee

6 Kadri Kangro⁴ kadri.kangro@icosagen.ee

7 Epp Sepp² epp.sepp@ut.ee

8 Virge Jürjenson¹ virge.jurjenson@synlab.ee

9 Jaanika Kärner³ jaanika.karner@ut.ee

10 Liis Haljasmägi³ liis.haljasmagi@ut.ee

11 Uku Haljasorg³ uku.haljasorg@ut.ee

12 Marilin Kuusk⁴ marilin.kuusk@icosagen.ee

13 Joachim M. Gerhold⁴ joachim.gerhold@icosagen.ee

14 Anu Planken^{4,5} anu.planken@icosagen.ee

15 Mart Ustav⁴ mart.ustav@ut.ee

16 Kai Kisand³, kai.kisand@ut.ee

17 Pärt Peterson^{3*} part.peterson@ut.ee

18

19

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

20 **Affiliations:** ¹ SYNLAB Estonia, Tallinn, Estonia; ² Department of Microbiology, Institute of Biomedicine and
21 Translational Medicine, University of Tartu, Tartu, Estonia; ³ Molecular Pathology, Institute of Biomedicine
22 and Translational Medicine, University of Tartu, Tartu, Estonia; ⁴ Icosagen Cell Factory, Õssu, Kambja,
23 Estonia; ⁵ Department of Oncology, North-Estonian Medical Centre, Tallinn, Estonia. *These authors
24 contributed equally to this work.

25

26 **Correspondence:** Dr. Paul Naaber, paul.naaber@synlab.ee; Veerenni 53a, 10138 Tallinn Estonia, Kai Kisand,
27 kai.kisand@ut.ee, Ravila 9, University of Tartu, 50411, Tartu, Estonia and Pärt Peterson,
28 part.peterson@ut.ee, Ravila 9, University of Tartu, 50411, Tartu, Estonia

29

30 **Keywords:** SARS-CoV-2 mRNA vaccine, dynamics of the immune response, ACE2-spike inhibition, T cell
31 response, adverse effects

32

33

34 **Abstract**

35 The high number of mutations in the Omicron variant of SARS-CoV-2 cause its immune escape when compared
36 to the earlier variants of concern (VOC). At least three vaccine doses are required for the induction of Omicron
37 neutralizing antibodies and further reducing the risk for hospitalization. However, most of the studies have
38 focused on the immediate response after the booster vaccination while the duration of immune response is
39 less known. We here studied longitudinal serum samples from the vaccinated individuals up to three months
40 after their third dose of the BNT162b2 vaccine for their capacity to produce protective antibodies and T cell
41 responses to Wuhan and Omicron variants. After the second dose, the antibody levels to the unmutated spike
42 protein were significantly decreased at three months, and only 4% of the individuals were able to inhibit
43 Omicron spike interaction compared to 47%, 38%, and 14% of individuals inhibiting wild-type, delta, and beta
44 variants' spike protein. Nine months after the second vaccination, the antibody levels were similar to the levels
45 before the first dose and none of the sera inhibited SARS-CoV-2 wild-type or any of the three VOCs. The
46 booster dose remarkably increased antibody levels and their ability to inhibit all variants. Three months after
47 the booster the antibody levels and the inhibition activity were trending lower but still up and not significantly
48 different from their peak values at two weeks after the third dose. Although responsiveness towards mutated
49 spike peptides was lost in less than 20 % of vaccinated individuals, the wild-type spike-specific CD4+ and CD8+
50 memory T cells were still present at three months after the booster vaccination in the majority of studied
51 individuals. Our data show that two doses of the BNT62b2 vaccine are not sufficient to protect against the
52 Omicron variant, however, the spike-specific antibodies and T cell responses are strongly elicited and well
53 maintained three months after the third vaccination dose.

54 Introduction

55 The Omicron variant of SARS-CoV-2 has caused breakthrough infections worldwide among previously
56 vaccinated individuals showing that the antibody levels formed after the vaccination are not sufficient to
57 inhibit its transmission ¹. The variant has many new mutations compared to previous variants of concern
58 (VOCs), which has enabled an escape from neutralizing antibodies and added to its transmission efficiency in
59 communities ². Many of the mutations are located in spike protein that is needed for the virus entry to human
60 cells and is targeted by most of the currently available vaccines ³.

61 Despite increased infections, the risk for severe disease and hospitalization with Omicron among vaccinated
62 individuals is reduced compared to earlier variants, including Delta ⁴. As one reason, animal studies have
63 shown that Omicron was limited to the upper respiratory tract causing less damaging infection in the lungs,
64 and these findings have been supported by human ex vivo studies ⁵. Secondly, the high number of mutations
65 in spike protein has added to its ability to escape from neutralizing antibodies and develop resistance to
66 therapeutic antibodies in clinical use ⁶⁻¹¹. The variant efficiently escapes from the neutralizing antibodies in
67 individuals who have been vaccinated with two doses of mRNA vaccine ^{7,10}. However, the third dose of mRNA
68 vaccine has been reported to prominently induce neutralizing antibodies against the Omicron variant
69 inhibiting the loss of neutralizing activities ¹⁰. Furthermore, the breakthrough infection by non-Omicron variant
70 robustly elicits Omicron-neutralizing antibodies in the vaccinees who have received mRNA vaccines ¹²,
71 suggesting that three contacts with the viral antigen either in form of vaccination or breakthrough infections
72 are sufficient to avoid severe Covid-19. Thus, the hospitalization with the Omicron variant was found 65% and
73 80% lower for those who received 2 or 3 doses, respectively, when compared to those who had not received
74 any vaccination ^{13 14,15}. Apart from the neutralizing antibodies, the vaccination and previous infections with
75 SARS-CoV-2 induced robust CD4+ and CD8+ T cell responses that largely cross-reacted with Omicron despite
76 its high rate of spike gene mutations ¹⁶⁻¹⁸.

77 In addition to the number of vaccinations, another critical factor influencing the immune response to the SARS-
78 CoV-2 is the time since the mRNA vaccinations ¹⁹. As the antibody levels wane in vaccinated individuals over

79 time, these two factors need to be considered in intraindividual and longitudinal analyses of vaccinated
80 cohorts to identify the antibody and T cell responses elicited after the vaccinations. However, most of the
81 studies have analyzed the immune response shortly after the booster and there is limited data on the
82 durability of the effect of the third dose on Omicron neutralization.

83 We have followed a cohort of individuals vaccinated with the BNT162b2 vaccine and longitudinally measured
84 their antibody levels and T cell responses to Omicron variant up to three months after the third dose of
85 vaccination. We measured serum capacity to block Omicron spike interaction with ACE2 receptor after each
86 vaccination dose and compared this to previous VOCs. The prevalence of spike-specific CD4+ and CD8+ T cells
87 was studied before and after the booster vaccination and responses towards Omicron mutation peptide pool
88 were compared to the ones elicited by peptides derived from Wuhan spike.

89 **Results**

90 **Study group.** We studied a cohort of diagnostics lab personnel vaccinated with three doses of the BNT162b2
91 vaccine, which we have earlier followed for their second dose vaccine response ²⁰. The details of the study
92 groups are given in **Table 1**. Briefly, the cohort received the first and the second vaccination dose in January
93 2021, and the third nine months after the start of the trial in October 2021, with their last blood sample
94 collected at the end of January 2022. The collected samples included nine different time points collected
95 before and after the three-dose vaccination; these were before the first dose (B1D), before the second dose
96 (B2D), one week after the second dose (1wA2D), six weeks after the second dose (6wA2D), three months after
97 the second dose (3mA2D), 6 months after the second dose (6mA2D), 9 months after the second dose (9mA2D),
98 two weeks after the third dose (2wA3D) and 3 months after the third dose (3mA3D).

99 **SARS-CoV-2 antibody dynamics after three-dose vaccination.** Before the third vaccination, which was given
100 nine months after the second dose (9mA2D), the S-RBD IgG levels were significantly declined (median 739
101 AU/mL; IQR 419 – 1359; $p < 0.0001$) compared to the second dose of vaccination (**Figure 1, Table 1**). Two weeks
102 after the third dose (2wA3D) S-RBD IgG levels increased to a median 32899 AU/mL (IQR 17914 – 46718;
103 $p < 0.0001$) as compared to the pre-vaccination (9mA2D) time point. However, 3 months after the third dose

104 (3mA3D), the S-RBD IgG levels were trending lower (median 13119 AU/mL; IQR 6149-21767) but significantly
105 not different from 2wA3D ($p= 0.0713$). As in earlier timepoints ²⁰, the age of vaccinated individuals had a
106 significant negative correlation with S-RBD IgG response before (9mA2D: $r= -0.30$, $p=0.009$), and after the third
107 dose (2wA3D: $r= -0.31$, $p=0.015$; 3mA2D: $r=-0.39$, $p=0.004$).

108 **Serum inhibition of trimeric spike RBD-ACE2 interaction.** We next studied the effectiveness of two and three
109 vaccination doses for their potential to neutralize cell entry of the Omicron variant in comparison to other
110 VOCs. For this, we used an established experimental assay that measures the serum capacity to block the
111 angiotensin-converting enzyme 2 (ACE2) receptor interaction with the SARS-CoV-2 trimeric S protein RBD and
112 thus indicating neutralizing capacity. Using the assay, we tested the longitudinal serum samples from the
113 vaccinated individuals for their inhibition of SARS-CoV-2 Omicron, Delta, Beta, and wild-type spike protein
114 interaction.

115 Expectedly, the samples from unvaccinated time points did not inhibit the spike-ACE2 interaction of Omicron
116 or any other variant (**Figure 2 and 3, Table 1**). At 1wA2D, most samples were able to block the WT SARS-CoV-
117 2 (98%) and Delta (96%), and slightly less Beta (80%) VOC, however the capacity to inhibit the Omicron variant
118 was significantly less efficient ($p<0.0001$ compared to all other variants) with only 41% of samples below the
119 inhibition threshold (relative OD 0.75). The blocking capacity decreased over time and was lower for all
120 variants at 3mA2D, most prominently for Omicron (WT 47%, Delta 39%, Beta 14%, and Omicron 4%). Before
121 the third dose, at 9mA2D, the efficiency to block spike binding was further declined with less than 6% of serum
122 samples over the threshold value for all variants, indicating that the time after the second dose had a strong
123 effect on active immune protection but increasingly declined thereafter. After the administration of the third
124 dose at 2wA3D, all samples recovered their blocking activity and were able to inhibit the binding of the spike
125 protein of wild-type, Beta, and Delta VOCs. Nevertheless, 5.5% of the sera did not reach the threshold even
126 after three-dose vaccination when the spike of the Omicron variant was tested (**Figure 2 and 3**). At the last
127 time point, three months after the booster (3mA3D), all SARS-CoV-2 variant spike proteins were inhibited by
128 the majority of immunized sera (>80% of samples), however, the increase in medians (range 0.13 - 0.44 at

129 2wA3D vs 0.47 - 0.64 at 3mA3D) of the relative OD values for all variants suggested a diminished blocking
130 activity for all variants, consistent with S-RBD IgG results at 3mA3D.

131 Our previous study showed a strong correlation between the S-RBD IgG levels and blocking antibodies²⁰. The
132 Spearman rank correlation analysis at each vaccination point showed that, in contrast to other variants,
133 Omicron had a moderate correlation with S-RBD IgG and other VOCs ($r=0.57-0.63$) immediately after the
134 second dose (**Figure 4**). However, at subsequent sample collection points at 3mA2D and 9mA2D, we did not
135 find the Omicron results to correlate with S-RBD IgG or the inhibition capacity of other variants indicating a
136 deterioration of the protection against Omicron VOC. Strikingly, the Omicron variant's correlation with S-RBD
137 IgG and blocking capacity to other variants was restored after the booster dose ($r=-0.85$ for IgG RBD and $r>0.90$
138 for the inhibition experiments) and maintained a very strong correlation even at 3mA3D ($r=-0.83$ for IgG RBD
139 and $r>0.92$ for the inhibition experiments). These data strongly support the requirement of three doses to gain
140 protective antibodies against Omicron.

141 **T cell responses.** Several studies have reported stable or slightly diminished T cell responses to Omicron VOC
142 immediately after the booster dose. We here investigated the percentage of activation-induced marker
143 positive (AIM) memory T cells in CD4+ and CD8+ T cell compartments before and after the third dose, and the
144 Omicron-specific CD4+ and CD8+ T cell responses at three months after the booster dose (3mA3D). We found
145 84% and 58% of vaccinated individuals to have CD4+ and CD8+ memory responses before the third dose at
146 9mA2D (**Figure 5**) while the percentage of AIM+ CD4+ or CD8+ T cells was not significantly different from the
147 values measured 6 months earlier at 3mA2D. Administration of the third dose (2wA3D) increased these
148 percentages to 100% and 90%. The frequency of S-specific T cells was significantly higher in 2wA3D group
149 among CD4+ (median/IQR: 0.49/0.3 – 0.82) compared to 9mA2D (0.18/0.06 – 0.38; $p<0.0001$) and CD8+ T cells
150 (median/IQR: 0.31/0.13 – 0.45 vs 0.04/0 – 0.24; $p<0.0001$). At 3mA3D 97% of the vaccinees still harboured S-
151 specific CD4+ T cells (median/IQR: 0.34/0.23 – 0.61) and 79% had AIM+ CD8+ T cells (median/IQR: 0.11/0.04
152 – 0.27) that was not significantly different from the previous time point for CD4+ T cells, but slightly decreased

153 for CD8+ T cells. At 3mA3D AIM+ CD4+ T cell percentage correlated negatively with age ($r=-0.38$, $p=0.01$) and
154 positively with S-RBD IgG ($r=0.34$; $p=0.025$).

155 As the Omicron variant has significantly fewer fully conserved spike epitopes for CD4+ and CD8+ T cells than
156 the previous VOCs²¹, T cell responses induced by mRNA vaccines coding Wuhan spike, could be also affected.
157 To check this scenario, we performed in parallel T cell stimulation with the peptide pool containing only
158 mutated peptides from Omicron spike (SARS-CoV-2 Prot_S B.1.1.529 Mutation Pool from Miltenyi Biotec) at
159 3mA3D. We found that only 17% and 15% of the vaccinated individuals with AIM+ T cells towards Wuhan
160 spike, had lost responsiveness against the mutated epitopes by CD4+ and CD8+ T cells respectively.

161 Collectively, these results showed that the majority of the vaccinated individuals developed efficient SARS-
162 CoV-2 virus-specific memory T cell responses after the second dose, the response was boosted after the third
163 dose, and that both CD4+ and CD8+ memory T cells to the viral antigen persisted at three months after the
164 booster, albeit with slightly lower T cell response against the Omicron variant.

165 **Predictors of vaccine response.** Altogether 97% of participants reported adverse effects after the third dose.
166 The frequency and severity of side effects after the third dose were similar to those after the second dose
167 (total score median/IQR: 7/3 – 12 vs 6/2 – 12; $p=0.7$). The common side effects after the third dose were pain
168 or swelling at the injection site (in 90%), fatigue (69%), myalgia (51%), malaise (47%), headache (47%) and
169 chills (36%), and resembled those after the second dose.

170 We found a significant correlation of severity of side effects after the third and the second dose ($r= 0.48$,
171 $p=0.0003$). Thus, the individuals with pronounced side effects after the second dose also tended to have these
172 after the third one. The total score of adverse effects after the third dose significantly correlated with the
173 antibody response to S-RBD ($r= 0.53$, $p=0.001$), similar to the effect that we previously reported after the
174 second vaccine dose²⁰.

175

176

177 **Discussion**

178 Omicron has demonstrated its immune evasion among vaccinated individuals. We here investigated the
179 dynamics of neutralizing antibodies to Omicron, Beta and Delta VOCs, and original wild-type virus, and studied
180 samples of the vaccinated cohort for their capacity to inhibit spike protein interaction with ACE2. Among the
181 emerged VOCs, the Beta and Omicron variants have a greater ability to escape from neutralizing antibodies
182 and Omicron in particular can escape from the neutralizing antibodies in those who have received two mRNA
183 vaccine doses.

184 Consistent with previous reports ^{2,8,11}, we found decreased capacity to block Omicron in vaccinated serum
185 samples. This was particularly obvious after the second vaccine dose when less than half of the vaccinated
186 sera were able to inhibit the reaction, whereas the Beta variant was blocked by most (80%), and wild-type
187 virus and Delta VOC by more than 95% of the samples. However, the blocking efficiency declined over time
188 and at 9 months after the second dose, all serum samples had lost their blocking activity. Together with the
189 significant waning of the S-RBD binding, this result suggests a remarkable decline of protective antibodies at
190 9 months after the initial two BNT62b2 vaccine doses. However, two weeks after the booster dose, the serum
191 samples regained their blocking activity, which was in line with the elevated antibody levels to S-RBD.

192 Given the weaker serum activity generated against Omicron's spike protein, it was important to determine
193 whether the blocking antibody response stays durable in individuals who received the third dose of mRNA
194 vaccine. For this, we measured the antibodies to S-RBD and VOCs three months after the third dose. After
195 their peak values immediately after the third dose, the antibodies to spike RBD were lower three months later.
196 The decline was not significant, however, and was in their median values almost equal to the levels at 1.5
197 months after the second dose (median 12752 AU/mL, IQR 8209-7538 for 6wA2D vs median 12729 AU/mL, IQR
198 628-19883 for 3mA3D). The result indicates that over time the antibodies tend to decline after the booster
199 dose albeit more slowly than after the second dose. Interestingly the antibody blocking efficiency after the
200 third dose remained on the same level for wild-type but was slightly declining with VOCs. Nevertheless,
201 individual serum samples retained a strong correlation between S-RBD levels and the blocking capacity of wild

202 type and the variants, including Omicron. This is in contrast to the inhibition activity that we saw after the
203 second dose, where protection against Omicron did not correlate with S-RBD IgG antibody levels and was
204 discordant from the inhibition of wild-type, Beta, and Delta VOCs. The additional booster dose may elicit
205 Omicron-neutralizing memory B cell subsets and expand the repertoire of the broadly neutralizing antibodies
206 ²². In this case, it is plausible that the Omicron-neutralizing clones were acquired as a result of affinity
207 maturation of those with neutralizing activity to previously recognized wild-type spike vaccine antigen.

208 The waning of antibody levels over time and the emergence of immune escape mutants have turned the
209 focus towards antigen-specific T cells as important players in preventing serious COVID-19 ²³. The durability
210 of cellular response is one of the key parameters to consider in planning future booster vaccination
211 strategies. mRNA vaccines have shown potent induction of Spike-specific CD4+ and CD8+ responses by the
212 first two vaccine doses but significant contraction of the number of circulating antigen-specific T cells during
213 the first 3 months that stabilize thereafter ^{19,24}. This was evident also in our study: the percentages of AIM+
214 CD4+ and CD8+ T cells were stable between 3 and 9 months after the second dose. However, we
215 demonstrated here that the booster dose of BNT162b2 increased the percentage of both subtypes of Spike-
216 reactive T cells. This is in line with recent reports that have measured immune responses shortly after the
217 booster dose ²⁵. Importantly, we found that Spike-specific CD4+ T cell percentages were still elevated 3
218 months after the third dose of BNT162b2, and AIM+ CD8+ T cells showed only a moderate decline in
219 comparison to 2wA3D time point.

220 Another important concern about the mRNA vaccine induced T cell response is its cross-reactivity towards
221 VOCs. The Omicron variant has multiple mutations in its spike protein and in comparison to previous VOCs is
222 associated with the fewest fully conserved spike epitopes (72% for CD4+ and 86% for CD8+) ²¹. This means
223 that nevertheless the majority of T cell epitopes are unaffected by the Omicron spike mutations. Indeed,
224 several studies have already confirmed that T-cell reactivity to the Omicron variant is rather well preserved in
225 the majority of vaccinated individuals ^{16,17,21,25,26}. At 3mA3D we stimulated PBMC samples in parallel with
226 overlapping peptide pools spanning the entire spike protein sequence of the Wuhan strain or a selected pool

227 of peptides mutated in the Omicron spike. It has been predicted that approximately 70% of the mutated
228 Omicron sequences retain HLA class I binding capacity ²¹, e.g. due to conservative substitutions or changes
229 that don't impact HLA binding. Our findings are in line with these estimations as only less than 20% of the
230 studied individuals had lost responsiveness towards the mutation pool.

231 In sum, our results suggest increased durability of humoral and cellular immune responses towards SARS-CoV-
232 2 spike protein after the booster dose of BNT62b2 vaccine and confirm the notion of increase in the breadth
233 of antibody response and preservation of T cell responses towards the Omicron variant.

234 **Material and Methods**

235 **Recruitment, sample, and data collection.** The study group and the blood sample collection procedures were
236 reported in our previous study ²⁰. Briefly, SYNLAB Estonia employees volunteering to be vaccinated (2 to 3
237 doses) with COVID-19 mRNA BNT162b2 (Comirnaty Pfizer-BioNTech) vaccine were invited to participate in the
238 study. Starting January 2021, the first two vaccine doses were given three weeks apart, and the third dose was
239 administered nine months after the second dose. The samples were taken before the first dose (B1D), before
240 the second dose (B2D), one week after the second dose (1wA2D), six weeks after the second dose (6wA2D),
241 three months after the second dose (3mA2D), 6 months after the second dose (6mA2D), 9 months after the
242 second dose (9mA2D), two weeks after the third dose (2wA3D) and 3 months after the third dose (3mA3D).
243 The information about the presence of side effects after the third dose was collected as reported previously²⁰.

244 The study has been approved by the Research Ethics Committee of the University of Tartu on February 15,
245 2021 (No 335/T-21). Participants signed informed consent before the recruitment into the study. The study
246 was performed in accordance with Helsinki Declaration and followed Good Laboratory Practice.

247 Description of study group is presented previously ²⁰. We excluded the participants diagnosed with COVID-19
248 before or during the study. The number of participants of each time point are presented in **Table 1**.

249 **Antibody testing.** Serum samples were analyzed for the IgG antibodies to SARS-CoV-2 Spike protein receptor-
250 binding domain (S-RBD) IgG using quantitative Abbott SARS-CoV-2 IgG chemiluminescent micro-particle
251 immunoassay (CLIA) on ARCHITECT i2000SR analyzer (Abbott Laboratories) as described previously ²⁰.

252 **ACE2-Spike interaction blocking assay.** The serum capacity to block the angiotensin-converting enzyme 2
253 (ACE2) receptor interaction with SARS-CoV-2 trimeric S protein receptor-binding domain (RBD) was tested
254 using IVD-CE SARS-CoV-2 Neutralizing Antibody ELISA kit (Icosagen) as described previously ²⁰. In brief, the
255 ELISA plates covered with SARS-CoV-2 trimeric S proteins of wild-type (wt, Wuhan), Beta (B.1.351), Delta
256 (B.1.617.2), and Omicron (B.1.1.529) VOCs (Icosagen) were incubated with serum samples in a 1/100 dilution
257 and probed with biotinylated ACE2-hFc protein (Icosagen). Streptavidin-Horseradish Peroxidase was used for
258 colorimetric detection and the light absorbance was measured at 450 nm as optical density (OD) values. The
259 OD values of the measured samples were divided by the mean value of the three repeated samples without
260 serum to obtain relative OD values. The samples with relative OD values of <0.75 (i.e. ≥ 0.75 was determined
261 as the limit of detection) were considered sufficient in blocking ACE2 binding.

262 **SARS-CoV-2 Spike-specific CD4+ and CD8+ memory T cell responses.** For CD4+ and CD8+ T cell response
263 analysis, freshly isolated PBMCs (2×10^6 cells) were stimulated with overlapping SARS-CoV-2 S peptide pool
264 (1 μ g/ml, Miltenyi Biotec, 15-mer sequences with 11 amino acid overlap), and with anti-CD28 and anti-CD49d
265 for 20 hours. CEFX peptides (JPT Peptides) were used as a positive control. After the stimulation T cells were
266 stained for CD3 Brilliant Violet 650, CD4 Alexa Fluor 700, CD8 Brilliant Violet 605, CCR7 Alexa Fluor 488,
267 CD45RA APC, CD69 Brilliant Violet 510, OX40 PE-Dazzle (all from Biolegend), and CD137 PE (from Miltenyi
268 Biotec). Antigen-specific cells were gated according to the upregulation of activation-induced markers (AIM)
269 CD137 and CD69 in memory CD8+ T cells and CD137, OX40, and CD69 in memory CD4+ T cells (percentage
270 calculated from total CD8+ or CD4+ cells respectively) as described and shown previously ²⁰. The percentage
271 of AIM positive cells in the negative control sample (diluent with costimulatory antibodies) was subtracted
272 from the value from the stimulated sample. The cut-off level for Spike-specific T cell positivity was drawn to
273 0.02% according to the data from six unvaccinated individuals. 7-AAD was used for the discrimination of dead

274 cells. Flow cytometry was performed using LSRFortessa (BD Biosciences) and the results were analyzed with
275 FCS Express 7 (DeNovo Software). The gating strategy used

276 **Statistical analyses.** GraphPad version 9 was used for statistical analyses and generation of box and whiskers
277 plots and correlation plots. Variables of data (S-RBD IgG, T cell results, and ACE2-Spike interaction inhibition
278 values, age, and the score of side effects) were considered non-normally distributed and are reported as
279 medians and interquartile range (IQR). Kruskal-Wallis test with subsequent Dunn's multiple comparison
280 testing was used to analyze the S-RBD IgG data and for T cell response data, Friedman test with Dunn's multiple
281 comparisons for ACE2-Spike interaction inhibition assay results. The correlations between S-RBD IgG values
282 and inhibition results and age or number of side effects were analyzed using Spearman's correlation with
283 confidence intervals of 95%. For statistical analyses p-values <0.05 were considered to be statistically
284 significant and p-values >0.0001 are reported as exact numbers.

285

286 **Acknowledgments**

287 We thank the participants of the study. The study was supported by The Centre of Excellence for Genomics
288 and Translational Medicine funded by EU European Regional Development Fund (Project No.2014-
289 2020.4.01.15-0012), and the Estonian Research Council grant PRG377, PRG1117, Icosagen Cell Factory, and
290 SYNLAB Estonia.

291

292 **Declaration of interests**

293 The authors have nothing to disclose.

294

295 **Data and code availability**

296 Data required to reanalyze the data reported in this paper in pseudonymized form is available from the
297 corresponding author upon request.

298

299 **Figure Legends**

300 **Figure 1. Antibody responses in individuals vaccinated with BNT162b2 vaccine up to three months after the**
301 **third dose.** S-RBD IgG levels before vaccination (B1D), after the single vaccination (B2D); and 1 week (1wA2D);
302 6 weeks (6wA2D); 3 months (3mA2D); 6 months (6mA2D); 9 months (9mA2D) after the second vaccination
303 dose and 2 weeks (2wA3D) and 3 months (3mA3D) after the third vaccination dose. The dot plot comparisons
304 were performed with the Kruskal-Wallis test and Dunn's multiple testing correction; p-values >0.0001 are
305 reported as exact numbers.

306 **Figure 2. Inhibition of ACE2-trimeric Spike interaction by vaccine-induced antibodies.** Serum antibody
307 capacities to block the interaction of ACE2 receptor and Spike protein of wild type, Beta, Delta and Omicron
308 variants before the first dose (B1D), at 1 week (1wA2D), 3 months (3mA2D) and 9 months after the second

309 dose, and 2 weeks (2wA3D) and 3 months (3mA3D) after the third dose of vaccinations. The dotted line
310 indicates the relative OD value of 0.75, which is a threshold for sufficient blocking of ACE2 binding. The
311 matched data analysis was performed with the Friedman test with Dunn's multiple testing correction; p-
312 values >0.0001 are reported as exact numbers. The percentage of samples that were able to reach the
313 threshold of blocking activity is shown below each graph.

314

315 **Figure 3. The dynamics of the ACE2 inhibition capacity of wild-type virus, and Beta, Delta and Omicron**
316 **VOC spike proteins over time.** Each line corresponds to one viral strain, the data points show the median
317 values and error bars interquartile ranges of samples collected over time: before the first dose (B1D), 1 week
318 (1wA2D), 3 months (3mA2D), 9 months (9mA2D) after the second dose, 2 weeks (2wA3D) and 3 months
319 (3A3D) after the third dose. The second and third vaccination points are shown at corresponding weeks on
320 X-axis as 2D and 3D, respectively. The relative optical density (OD) values on the inverted Y-axis show the
321 inhibition activity. The value over 0.75 relative OD is considered as the threshold of the serum sample to
322 block ACE2-spike interaction.

323 **Figure 4. Correlation between serum S-RBD antibody levels and the inhibition capacity of ACE2-spike**
324 **interactions.** Spearman rank correlation analysis at each sample collection time after two and three
325 vaccination doses. Neutralization data is in relative optical density (OD) values with inverted direction (lower
326 values indicate stronger inhibition) and hence they are in negative correlation with S-RBD IgG (blue) and
327 positive correlation (red) between each other.

328 **Figure 5. Spike-specific T cell responses in vaccinated individuals.** Postvaccination frequency of S-specific
329 (A) CD4⁺ and (B) CD8⁺ T cells at 3 months (3mA2D), 9 months after the second dose (9mA2D), 2 weeks after
330 the third vaccination dose (2wA3D) and 3 months after the third dose (3mA3D). Red dots represent the
331 percentage of T cells that responded to peptide pools derived from Wuhan variant spike sequence and blue
332 dots correspond to the percentage of T cells that responded to peptide pool consisting selectively from

333 Omicron mutated sequences. The data were analysed with the Kruskal-Wallis test with Dunn's multiple
334 testing correction. The percentage of samples that had spike responsive T cells is shown below each graph.
335

336 **Table 1.** Summary results at different time-points

	Study groups/time-points								
	B1D	B2D	1wA2D	6wA2D	3mA2D	6mA2D	9mA2D	2wA3D	3mA3D
Antibodies to S-RBD									
IgG (AU/mL) median/IQR (n)	1.25/ 0.3- 2.5 (88)	1246/ 666- 2582 (111)	24534/ 13985-36616 (106)	12752/ 8225- 17348 (89)	5226/3097- 6924 (90)	1383/893 -2463 (84)	739/419- 1359 (73)	32899/179 14-46718 (60)	13119/ 6149- 21767 (51)
Inhibition of Spike-ACE2 interaction (relative OD)									
SARS-CoV-2 (wild type) median/IQR (n)	0.97/0.95- 0.99 (49)		0.33/0.13- 0.46 (49)		0.76/0.64- 0.83 (49)		0.92/0.86- 0.96 (71)	0.13/0.07- 0.33 (56)	0.55/0.31- 0.70 (51)
Beta (B.1.351) median/IQR (n)	1.00/0.97- 1.01 (9)		0.64/0.50- 0.71 (49)		0.86/0.79- 0.91 (49)		0.90/0.86- 0.96 (71)	0.23/0.14- 0.42 (56)	0.47/0.26- 0.6 (51)
Delta (B.1.617.2) Median/IQR (n)	0.99/0.97- 1.02 (49)		0.46/0.29- 0.58 (49)		0.80/0.68- 0.84 (49)		0.89/0.86- 0.95 (71)	0.16/0.09- 0.36 (56)	0.59/0.41- 0.73 (51)
Omicron (B.1.1.529) Median/IQR (n)	0.96/0.92- 1.03 (48)		0.79/0.68- 0.85 (49)		0.90/0.81- 0.97 (49)		0.87/0.82- 0.97 (71)	0.44/0.31- 0.58 (56)	0.64/0.44- 0.73 (51)
T cells									
Spike-specific CD8+ T cells (% from CD8+, Median/IQR (n))					0.070/ 0.008- 0.153 (79)		0.045/0- 0.24 (68)	0.31/0.13- 0.45 (51)	0.11/0.04- 0.27 (43)
Spike-specific CD4+ T cells (% from CD4+, Median/IQR (n))					0.245/ 0.008- 0.510 (78)		0.185/0.06- 0.38 (68)	0.49/0.3- 0.82 (51)	0.34/0.23- 0.61 (43)
Omicron-specific CD8+ T cells (% from CD8+, Median/IQR (n))									0.06/0.01- 0.16 (43)
Omicron-specific CD4+ T cells (% from CD4+, Median/IQR (n))									0.14/0.06- 0.42 (43)

337 B1D - before the first dose, B2D - before the second dose, 1wA2D - one week after the second dose, 6wA2D -

338 six weeks after the second dose, 3mA2D - three months after the second dose, 6mA2D - 6 months after the


339 second dose, 9mA2D - 9 months after the second dose, 2wA3D - two weeks after the third dose, 3mA3D - 3

340 months after the third dose

341

342 **Figure 1**


343



344

345

346 **Figure 2**




347

348

349


350

351 **Figure 3**




352

353 Figure 4



354

355 **Figure 5**



356

357

358 **References**

- 359 1. Viana, R., Moyo, S., Amoako, D.G., Tegally, H., Scheepers, C., Althaus, C.L., Anyaneji, U.J., Bester,
360 P.A., Boni, M.F., Chand, M., et al. (2022). Rapid epidemic expansion of the SARS-CoV-2 Omicron
361 variant in southern Africa. *Nature*. 10.1038/s41586-022-04411-y.
- 362 2. Dejnirattisai, W., Huo, J., Zhou, D., Zahradnik, J., Supasa, P., Liu, C., Duyvesteyn, H.M.E., Ginn,
363 H.M., Mentzer, A.J., Tuekprakhon, A., et al. (2022). SARS-CoV-2 Omicron-B.1.1.529 leads to
364 widespread escape from neutralizing antibody responses. *Cell* 185, 467-484.e415.
365 10.1016/j.cell.2021.12.046.
- 366 3. Martin, D.P., Lytras, S., Lucaci, A.G., Maier, W., Grüning, B., Shank, S.D., Weaver, S., MacLean,
367 O.A., Orton, R.J., Lemey, P., et al. (2022). Selection analysis identifies unusual clustered mutational
368 changes in Omicron lineage BA.1 that likely impact Spike function. *bioRxiv*.
369 10.1101/2022.01.14.476382.
- 370 4. Veneti, L., Bøås, H., Bråthen Kristoffersen, A., Stålcrantz, J., Bragstad, K., Hungnes, O., Storm, M.L.,
371 Aasand, N., Rø, G., Starrfelt, J., et al. (2022). Reduced risk of hospitalisation among reported COVID-
372 19 cases infected with the SARS-CoV-2 Omicron BA.1 variant compared with the Delta variant,
373 Norway, December 2021 to January 2022. *Euro Surveill* 27. 10.2807/1560-
374 7917.ES.2022.27.4.2200077.
- 375 5. Hui, K.P.Y., Ho, J.C.W., Cheung, M.C., Ng, K.C., Ching, R.H.H., Lai, K.L., Kam, T.T., Gu, H., Sit, K.Y.,
376 Hsin, M.K.Y., et al. (2022). SARS-CoV-2 Omicron variant replication in human bronchus and lung ex
377 vivo. *Nature*. 10.1038/s41586-022-04479-6.
- 378 6. Liu, Y., Liu, J., Xia, H., Zhang, X., Zou, J., Fontes-Garfias, C.R., Weaver, S.C., Swanson, K.A., Cai,
379 H., Sarkar, R., et al. (2021). BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike
380 Variants. *N Engl J Med*. 10.1056/NEJMc2106083.
- 381 7. Cameroni, E., Bowen, J.E., Rosen, L.E., Saliba, C., Zepeda, S.K., Culap, K., Pinto, D., VanBlargan,
382 L.A., De Marco, A., di Iulio, J., et al. (2021). Broadly neutralizing antibodies overcome SARS-CoV-2
383 Omicron antigenic shift. *Nature*. 10.1038/s41586-021-04386-2.
- 384 8. Cele, S., Jackson, L., Khoury, D.S., Khan, K., Moyo-Gwete, T., Tegally, H., San, J.E., Cromer, D.,
385 Scheepers, C., Amoako, D.G., et al. (2021). Omicron extensively but incompletely escapes Pfizer
386 BNT162b2 neutralization. *Nature*. 10.1038/s41586-021-04387-1.

- 387 9. VanBlargan, L.A., Errico, J.M., Halfmann, P.J., Zost, S.J., Crowe, J.E., Purcell, L.A., Kawaoka, Y.,
388 Corti, D., Fremont, D.H., and Diamond, M.S. (2022). An infectious SARS-CoV-2 B.1.1.529 Omicron
389 virus escapes neutralization by therapeutic monoclonal antibodies. *Nat Med.* 10.1038/s41591-021-
390 01678-y.
- 391 10. Garcia-Beltran, W.F., St Denis, K.J., Hoelzemer, A., Lam, E.C., Nitido, A.D., Sheehan, M.L., Berrios,
392 C., Ofoman, O., Chang, C.C., Hauser, B.M., et al. (2022). mRNA-based COVID-19 vaccine boosters
393 induce neutralizing immunity against SARS-CoV-2 Omicron variant. *Cell* 185, 457-466.e454.
394 10.1016/j.cell.2021.12.033.
- 395 11. Carreño, J.M., Alshammary, H., Tcheou, J., Singh, G., Raskin, A., Kawabata, H., Sominsky, L., Clark,
396 J., Adelsberg, D.C., Bielak, D., et al. (2021). Activity of convalescent and vaccine serum against
397 SARS-CoV-2 Omicron. *Nature.* 10.1038/s41586-022-04399-5.
- 398 12. Rössler, A., Riepler, L., Bante, D., von Laer, D., and Kimpel, J. (2022). SARS-CoV-2 Omicron Variant
399 Neutralization in Serum from Vaccinated and Convalescent Persons. *N Engl J Med.*
400 10.1056/NEJMc2119236.
- 401 13. UKHSA (2021). SARS-CoV-2 variants of concern and variants under investigation in England
402 Technical briefing: Update on hospitalisation and vaccine effectiveness for Omicron VOC-21NOV-01
403 (B.1.1.529). In D. UK Health Security Agency, and o.H.a.S. Care, eds. UK Health Security Agency.
- 404 14. Wratil, P.R., Stern, M., Priller, A., Willmann, A., Almanzar, G., Vogel, E., Feuerherd, M., Cheng, C.C.,
405 Yazici, S., Christa, C., et al. (2022). Three exposures to the spike protein of SARS-CoV-2 by either
406 infection or vaccination elicit superior neutralizing immunity to all variants of concern. *Nat Med.*
407 10.1038/s41591-022-01715-4.
- 408 15. Wolter, N., Jassat, W., Walaza, S., Welch, R., Moultrie, H., Groome, M., Amoako, D.G., Everatt, J.,
409 Bhiman, J.N., Scheepers, C., et al. (2022). Early assessment of the clinical severity of the SARS-CoV-
410 2 omicron variant in South Africa: a data linkage study. *Lancet* 399, 437-446. 10.1016/S0140-
411 6736(22)00017-4.
- 412 16. Keeton, R., Tincho, M.B., Ngomti, A., Baguma, R., Benede, N., Suzuki, A., Khan, K., Cele, S.,
413 Bernstein, M., Karim, F., et al. (2022). T cell responses to SARS-CoV-2 spike cross-recognize
414 Omicron. *Nature.* 10.1038/s41586-022-04460-3.

- 415 17. Gao, Y., Cai, C., Grifoni, A., Müller, T.R., Niessl, J., Olofsson, A., Humbert, M., Hansson, L.,
416 Österborg, A., Bergman, P., et al. (2022). Ancestral SARS-CoV-2-specific T cells cross-recognize the
417 Omicron variant. *Nat Med.* 10.1038/s41591-022-01700-x.
- 418 18. Liu, J., Chandrashekar, A., Sellers, D., Barrett, J., Jacob-Dolan, C., Lifton, M., McMahan, K., Sciacca,
419 M., VanWyk, H., Wu, C., et al. (2022). Vaccines Elicit Highly Conserved Cellular Immunity to SARS-
420 CoV-2 Omicron. *Nature.* 10.1038/s41586-022-04465-y.
- 421 19. Goel, R.R., Painter, M.M., Apostolidis, S.A., Mathew, D., Meng, W., Rosenfeld, A.M., Lundgreen,
422 K.A., Reynaldi, A., Khoury, D.S., Pattekar, A., et al. (2021). mRNA vaccines induce durable immune
423 memory to SARS-CoV-2 and variants of concern. 10.1126/science.abm0829.
- 424 20. Naaber, P., Tserel, L., Kangro, K., Sepp, E., Jürjenson, V., Adamson, A., Haljasmägi, L., Rumm, A.P.,
425 Maruste, R., Kärner, J., et al. (2021). Dynamics of antibody response to BNT162b2 vaccine after six
426 months: a longitudinal prospective study. *Lancet Reg Health Eur* 10, 100208.
427 10.1016/j.lanep.2021.100208.
- 428 21. Tarke, A., Coelho, C.H., Zhang, Z., Dan, J.M., Yu, E.D., Methot, N., Bloom, N.I., Goodwin, B., Phillips,
429 E., Mallal, S., et al. (2022). SARS-CoV-2 vaccination induces immunological T cell memory able to
430 cross-recognize variants from Alpha to Omicron. *Cell.* 10.1016/j.cell.2022.01.015.
- 431 22. Kotaki, R., Adachi, Y., Moriyama, S., Onodera, T., Fukushi, S., Nagakura, T., Tonouchi, K., Terahara,
432 K., Sun, L., Takano, T., et al. (2022). SARS-CoV-2 Omicron-neutralizing memory B-cells are elicited
433 by two doses of BNT162b2 mRNA vaccine. *Sci Immunol*, eabn8590. 10.1126/sciimmunol.abn8590.
- 434 23. Sette, A., and Crotty, S. (2021). Adaptive immunity to SARS-CoV-2 and COVID-19. *Cell* 184, 861-
435 880. 10.1016/j.cell.2021.01.007.
- 436 24. GeurtsvanKessel, C.H., Geers, D., Schmitz, K.S., Mykytyn, A.Z., Lamers, M.M., Bogers, S.,
437 Scherbeijn, S., Gommers, L., Sablerolles, R.S.G., Nieuwkoop, N.N., et al. (2022). Divergent SARS
438 CoV-2 Omicron-reactive T- and B cell responses in COVID-19 vaccine recipients. *Sci Immunol*,
439 eabo2202. 10.1126/sciimmunol.abo2202.
- 440 25. Liu, Y., Zeng, Q., Deng, C., Li, M., Li, L., Liu, D., Liu, M., Ruan, X., Mei, J., Mo, R., et al. (2022).
441 Robust induction of B cell and T cell responses by a third dose of inactivated SARS-CoV-2 vaccine.
442 *Cell Discov* 8, 10. 10.1038/s41421-022-00373-7.

- 443 26. Naranbhai, V., Nathan, A., Kaseke, C., Berrios, C., Khatri, A., Choi, S., Getz, M.A., Tano-Menka, R.,
444 Ofoman, O., Gayton, A., et al. (2022). T cell reactivity to the SARS-CoV-2 Omicron variant is
445 preserved in most but not all individuals. *Cell*. 10.1016/j.cell.2022.01.029.

446